Open an account

Ocular Therapeutix

OCUL · NASDAQ

$6.65+$0.36 (+5.72%)TodayMarket closed ·
Prev close $6.29

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 325 full-time employees. The company went IPO on 2014-07-25. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.

Employees
325
Headquarters
Bedford, Massachusetts
Listed
Jul 25, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
ocutx.com

OCUL key statistics

Market cap
1.46B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.54M
Volume
2.62M
Open price
$6.30
High today
$6.78
Low today
$6.30
52 Week high
$16.44
52 Week low
$6.00

Ocular Therapeutix (OCUL) at a glance

Ocular Therapeutix (OCUL) last traded at $6.65, with a market cap of 1.46B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.30 and $6.78. The current price is 5.6% above the day's low and 1.8% below its high.

Volume so far is 2.62M shares, below the average of 3.54M shares a day.

Over the past year Ocular Therapeutix has ranged from $6.00 to $16.44, and now sits 6% of the way up that range.

Ocular Therapeutix met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.35 per share against an estimate of -$0.4034.

The average analyst price target is $27.26, 310.0% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 13 analystsAvg $27.26
Low
$18.18
Now
$6.65
High
$35.70

OCUL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 12.3% on average.

  1. Q3 FY24: reported -$0.22 per share against an estimate of -$0.2471
  2. Q4 FY24: reported -$0.29 per share against an estimate of -$0.2567
  3. Q1 FY25: reported -$0.38 per share against an estimate of -$0.3001
  4. Q2 FY25: reported -$0.39 per share against an estimate of -$0.3617
  5. Q3 FY25: reported -$0.38 per share against an estimate of -$0.374
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.3323
  7. Q1 FY26: reported -$0.40 per share against an estimate of -$0.3185
  8. Q2 FY26: reported -$0.35 per share against an estimate of -$0.4034

OCUL news

  • Vandana Singh

    Why Is Ocular Therapeutix Stock Gaining Monday?

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Vandana Singh

    Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program

  • Vandana Singh

    Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study

  • Ocular Therapeutix Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

  • Avi Kapoor

    Gold Down 3%; Medtronic Earnings Top Views

  • Vandana Singh

    Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes

  • Market-Moving News for February 17th

Similar companies

Companies in the same industry as Ocular Therapeutix

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.